GKB Ophthalmics (NSE:GKB) Growth Rank: 5 (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GKB GKB Ophthalmics Ltd NSE:GKB
44 GF Score
Price ₹63.00
GF Value ₹126.23
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GKB Ophthalmics Growth Rank?

GKB Ophthalmics NSE:GKB 44 Growth Rank is 5 as of Aug. 25, 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.23 (Significantly Undervalued). The stock has 5 warning signs investors should review.

GKB Ophthalmics has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

GKB Ophthalmics Growth Rank Related Terms

NSE:GKB vs ISRG, BDX, MDLN: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GKB Ophthalmics Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's Growth Rank distribution charts can be found below:

* The bar in red indicates where GKB Ophthalmics's Growth Rank falls into.


NSE:GKB
44GF Score
GKB Ophthalmics Ltd NSE:GKB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
GKB Ophthalmics (NSE:GKB) has a Growth Rank of 5 as of Aug. 25, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on GKB Ophthalmics and its competitors.
Is GKB Ophthalmics' Growth Rank too high?
GKB Ophthalmics' current Growth Rank is 5. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' Growth Rank compare to ISRG and BDX?
GKB Ophthalmics' Growth Rank of 5 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on GKB Ophthalmics and its competitors. GKB Ophthalmics's current Growth Rank is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.23, compared to a current price of ₹63.00 — trading 50.1% below its estimated fair value. The current Growth Rank is 5. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current Growth Rank is 5 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?

Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued. The current stock price of ₹63.00 is trading 50.1% below its estimated GF Value™ of ₹126.23. GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.

Key valuation signals for NSE:GKB:

  • Growth Rank: 5
  • GF Value™: ₹126.23 vs. price of ₹63.00 (50.1% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GKB Ophthalmics Business Description

Other Exchanges 533212:India
Address 16-A, Tivim Industrial Estate, Mapusa, GA, IND, 403 526
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score

Get the complete analysis for NSE:GKB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹63.00
Price
₹126.23
GF Value